Mowery, Y. M., Ballman, K. V., Hong, A. M., Schuetze, S. M., Wagner, A. J., Monga, V., . . . Kirsch, D. G. (2024). Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): An open-label, randomised clinical trial. The Lancet (British edition), 404(10467), 2053-2064. https://doi.org/10.1016/S0140-6736(24)01812-9
Citace podle Chicago (17th ed.)Mowery, Yvonne M., et al. "Safety and Efficacy of Pembrolizumab, Radiation Therapy, and Surgery Versus Radiation Therapy and Surgery for Stage III Soft Tissue Sarcoma of the Extremity (SU2C-SARC032): An Open-label, Randomised Clinical Trial." The Lancet (British Edition) 404, no. 10467 (2024): 2053-2064. https://doi.org/10.1016/S0140-6736(24)01812-9.
Citace podle MLA (9th ed.)Mowery, Yvonne M., et al. "Safety and Efficacy of Pembrolizumab, Radiation Therapy, and Surgery Versus Radiation Therapy and Surgery for Stage III Soft Tissue Sarcoma of the Extremity (SU2C-SARC032): An Open-label, Randomised Clinical Trial." The Lancet (British Edition), vol. 404, no. 10467, 2024, pp. 2053-2064, https://doi.org/10.1016/S0140-6736(24)01812-9.